Menu

Nordic Gene Study Requires Consent

A company has been ordered to stop estimating Icelanders’ genotypes and linking them to hospital records.

Jun 24, 2013
Kate Yandell

FLICKR, SHAURY NASHThe company deCODE Genetics is known for harnessing Iceland’s excellent genealogical records to aid in massive studies of genetics and disease. But according to an article in the Science print edition, Iceland’s Data Protection Authority (DPA) ruled last month (May 28) that the company must seek consent before continuing genetics studies using estimated data on 280,000 Icelanders—some living and some dead—who did not agree to be studied.

Already deCODE has published 6 papers in Nature and the New England Journal of Medicine using the data-collecting strategy, which involves estimating genotypes of relatives of 120,000 volunteers who did agree to let the company study their genetics. In some cases the company is able to link the estimated genetic data to hospital records of patients who volunteered to be part of another Icelandic research study, for which they did not consent to undergo genetic testing.

Kári Stefánsson, founder and CEO of deCODE, argues that the company, which is now owned by Amgen, is not violating patient privacy because it is not actually sequencing citizens’ DNA. “These are just conjectures about people, hypotheses,” he told Science.

The Icelandic government is giving the company until November to demonstrate they have obtained consent from their subjects.

(For a free online version of the article, see ScienceInsider.)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.